Fig. 3

Melanoma patients who responded to anti-CTLA-4 therapy had higher frequencies of memory T cells in baseline PBMC. CyTOF data from baseline PBMC of melanoma patients treated with anti-CTLA-4. Frequencies of (a) CD45RA⁺ cells in CD4⁺ and CD8⁺ T cell compartments; (b) CD45RA⁻ cells in CD4⁺ and CD8⁺ T cell compartments. c-f Memory subsets of CD4⁺ and CD8⁺ T cells in responders versus non-responders. c Frequencies of naïve (CD45RA⁺CCR7⁺) and Central Memory (Tcm, CD45RA⁻CCR7⁺) CD4⁺ T cells. d Frequencies of Effector Memory (Tem, CD45RA⁻CCR7⁻) and Terminal Effector (Teff, CD45RA⁺CCR7⁻) CD4⁺ T cells. c Frequencies of naïve (CD45RA⁺CCR7⁺) and Central Memory (Tcm, CD45RA⁻CCR7⁺) CD8⁺ T cells. d Frequencies of Effector Memory (Tem, CD45RA⁻CCR7⁻) and Terminal Effector (Teff, CD45RA⁺CCR7⁻) CD8⁺ T cells. *p < 0.05; **p < 0.01